Imidazole Dipeptide Agent for Cognitive Decline Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aging-related cognitive decline and dementia are significant health concerns, with existing solutions lacking effective, safe, and naturally derived agents for prevention and management.
Innovation Solution
An agent containing imidazole dipeptides, such as carnosine and anserine, derived from chicken, which can be ingested in doses of 200 mg or more, potentially combined with creatine and nucleic acids, to improve cognitive function, prevent cerebral atrophy, and manage dementia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for dementia and cognitive decline are used, then cognitive function may be improved, but safety concerns and lack of natural derivation arise
Solution Approach 1:
The patent changes the chemical parameter by using imidazole dipeptides (carnosine and anserine) which have specific imidazole ring structures. These natural compounds are derived from chicken and other natural sources, providing a safer alternative to conventional synthetic dementia treatments while maintaining cognitive function improvement effects
Solution Approach 2:
The patent combines multiple natural components including imidazole dipeptides (carnosine and anserine), creatine, and nucleic acids into a composite formulation. This composite approach leverages the synergistic effects of naturally derived substances to improve cognitive function while ensuring safety through natural origin of all components
2Reliability
If imidazole dipeptides are used to prevent dementia, then cognitive function improves and cerebral atrophy is suppressed, but the mechanism of action requires further clarification
Solution Approach 1:
The patent incorporates evaluation mechanisms using MRI to measure cerebral atrophy suppression and cognitive function tests to assess dementia prevention effects. This feedback approach allows for objective measurement of the treatment efficacy and helps clarify the mechanism of action through observable outcomes
Solution Approach 2:
The patent replaces complex mechanistic explanations with observable physiological outcomes. Instead of focusing on unknown molecular mechanisms, the patent uses MRI imaging to directly measure cerebral atrophy suppression and cognitive function tests to evaluate dementia prevention, substituting mechanical/physical measurement for theoretical mechanism understanding
Data Source
Figure 1~2
Figure 3-1~3-2
Figure 4~5
AI summary
An anti-aging agent derived from a natural product is provided. The agent uses at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof as an active ingredient. The present invention also provides an agent for improving a neuropsychologic function, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof as an active ingredient. The present invention also provides an agent for changing expression of a transporter such as SLC23A2, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof, and an agent for controlling blood concentration of a cytokine such as IP-10, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof, as well as an expression analysis method for detecting improvement or degradation of a neuropsychologic function, and a kit for detecting improvement or degradation of a neuropsychologic function.